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SUMMARY – Interleukin (IL)-10 is an anti-infl ammatory cytokine, and a decrease in its secre-
tion is associated with obesity, metabolic syndrome and type 2 diabetes. However, it has not been 
 established whether the intensity of the immune response during diabetes-associated chronic infl am-
mation aff ects the development and/or progression of type 2 diabetes and its microvascular compli-
cations. Th e aim of this study was to investigate the role of single nucleotide polymorphism 
(SNP)-1082G/A for IL-10 gene in development of diabetes type 2 and its complications. DNA was 
extracted from blood cells of 240 overweight/obese subjects for IL-10 genotyping. Based on the pres-
ence of diabetes type 2, patients were divided in two groups: experimental group of 144 patients with 
diabetes type 2 and control group of 96 age- and gender-matched subjects without diabetes. Com-
pared to control group, diabetic group had higher levels of leukocytes (p=0.012), fi brinogen (p=0.049) 
and plasminogen activator inhibitor-1 (PAI-1) (p=0.009), and lower levels of albumin (p=0.001). 
Th ere were no diff erences in the frequency of SNP-1082G/A for IL-10 gene between the two groups 
(p=0.654). When considering diabetes related traits in all subjects in relation to specifi c genotype, a 
group with homozygous (AA) genotype had higher values of the mean fasting glucose (p<0.000001), 
HbA1c (p<0.000001) and HOMA-IR (p=0.003632), while the mean HOMA-B value (p=0.000178) 
was lower when compared to the groups with GG and GA genotypes. Th ere was no diff erence in 
development of diabetic nephropathy, retinopathy and polyneuropathy between the IL-10 polymor-
phism genotypes. In conclusion, obese diabetes type 2 patients had an increased infl ammation activity 
compared to obese non-diabetic individuals. Th ere was no association of the investigated polymor-
phisms and development of type 2 diabetes and its microvascular complications. However, diabetes 
related traits clearly depended on the presence of specifi c IL-10 genotype.
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Introduction
Hypersecretion of proinfl ammatory cytokines (tu-
mor necrosis factor-α, interleukin (IL)-1, and IL-6) in 
overweight and obese individuals can cause insulin re-
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sistance in peripheral tissues1-4, as well as a decline in 
beta cell mass and function5-7, thus promoting develop-
ment of type 2 diabetes. Presumably, this eff ect can 
be countered by anti-infl ammatory cytokines such as 
IL-10, transforming growth factor-β, and adiponec-
tin8-12. Hence, the possibility exists that an imbalance in 
the activity of pro- and anti-infl ammatory cytokines has 
an important role in the pathogenesis of type 2 diabetes.
Polymorphisms in pro- and anti-infl ammatory cy-
tokine genes, as well as their receptors, may exacerbate 
this cytokine imbalance and thus also development of 
type 2 diabetes13-16. On the basis of genotype, there are 
‘high’ and ‘low’cytokine producers. By identifying spe-
cifi c polymorphisms in each cytokine gene, it is possi-
ble to identify high and low cytokine producers by 
genotype. Th erefore, in certain individuals, a genetic 
predisposition for a hyper-reactive immune response 
may be responsible for the development of type 2 dia-
betes. Furthermore, the progression of microvascular 
complications16-18 may be associated with polymor-
phisms in pro- and anti-infl ammatory cytokine genes. 
However, it has not been established whether the in-
tensity of the immune response during diabetes-asso-
ciated chronic infl ammation aff ects the development 
and/or progression of type 2 diabetes and its charac-
teristic microvascular complications.
Interleukin-10 is a primary anti-infl ammatory cy-
tokine, and according to previous reports, a decrease in 
its secretion is associated with obesity and metabolic 
syndrome, as well as hyperglycemia and type 2 diabe-
tes8,9,13,19. Th e IL-10 gene is located in the 1q32.1h ge-
nomic region. Within this region, a point mutation (G 
to A) at position -1082 is linked to low IL-10 expres-
sion13,19,20. Th e objective of this study was to determine 
the frequency of the IL-10 gene polymorphism, 
-1082G/A, in overweight/obese patients with type 2 
diabetes compared to overweight/obese non-diabetic 
controls, and to determine the possible link between 
this polymorphism and the fundamental pathophysi-
ological complications of type 2 diabetes such as insu-




Th is was a cross-sectional study that included 240 
subjects. Th e experimental group consisted of 144 
overweight or obese patients with type 2 diabetes, and 
the control group included 96 age- and sex-matched 
overweight or obese individuals without type 2 diabe-
tes. Subjects were recruited from the outpatient popu-
lation visiting Regional Center for Endocrinology and 
Metabolism Disorders, Osijek University Hospital 
Centre in Osijek and primary care physician practices 
in the Osijek-Baranja County, Croatia from 2010 to 
2013. Th is study complied with the Declaration of 
Helsinki and was approved by the Ethics Committee 
of the Osijek University Hospital Centre (reference 
number 29-1:6663/06). A written informed consent 
was obtained from each patient.
Patient inclusion criteria
Th e experimental group was required to meet the 
following inclusion criteria: diagnosis of type 2 diabe-
tes; diabetes treated with diet, exercise, or medications 
(not thiazolidinediones or insulin therapy); excessive 
body weight (body mass index (BMI) >25 kg/m2); and 
age 18-80 years. In the control group, type 2 diabetes 
was excluded based on the fasting glucose (<7 mmol/L) 
and glycated hemoglobin (HbA1c; <6.5%) levels, ac-
cording to the recommendations of the American 
Diabetes Association, International Diabetes Federa-
tion, and European Association for the Study of Dia-
betes. Patients with a history of the following condi-
tions were excluded from the study: type 1 diabetes; 
diabetes treated with insulin therapy; recent acute in-
fection regardless of localization; long-term treatment 
with immunomodulatory and anti-infl ammatory 
drugs; long-term therapies with possible pro-diabetic 
eff ects such as glucocorticoids, immunosuppressive 
drugs, and certain antidepressants used over a period 
of 3 months; endocrine disorders with secondary dia-
betes; other intercurrent diseases associated with acute 
or chronic infl ammation; history of acute pancreatitis 
or chronic pancreatitis; history of acute or chronic B or 
C hepatitis or HIV; or malignant disease within the 
past 5 years.
Methods
At study entry, medical history was obtained that 
included demographics, family history, disease diagno-
sis, risk factors for type 2 diabetes, presence of chronic 
complications, other relevant diseases, medications, 
and lifestyle habits. Physical examination was per-
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formed with standardized measurement of body 
weight, body height, waist circumference, and blood 
pressure. BMI was calculated from body weight and 
height (kg/m2). In addition, blood and urine samples 
were collected for biochemical analyses (fasting glu-
cose, HbA1c, liver enzymes, lipid profi le, creatinine, 
uric acid, total proteins, albumins, leukocytes, C-reac-
tive protein (CRP), plasminogen activator inhibitor-1 
[PAI-1], and fi brinogen), evaluation of complications 
(endogenous creatinine clearance, 24-hour urine pro-
tein, and 24-hour urine albumin excretion), hormone 
analysis (insulin, C-peptide, thyroid-stimulating hor-
mone (TSH), cortisol, sex hormone binding globulin 
(SHBG)), and DNA isolation, to determine the pres-
ence and eff ects of the gene polymorphism. All pa-
tients underwent neurological and ophthalmological 
examinations. Biochemical and urine analyses were 
performed using established methods in the Central 
Laboratory of the Osijek University Hospital Centre.
To assess glucose metabolism, the following pa-
rameters were chosen: fasting glucose, HbA1c, insulin, 
C-peptide, homeostatic model assessment index of in-
sulin resistance (HOMA-IR), and homeostatic model 
assessment index of beta cell function (HOMA-B). 
HOMA-IR and HOMA-B were calculated using the 
following formulae: HOMA-IR = glucose (mmol/L) 
× insulin (mIU/L)/22.5; HOMA-B = 20 × insulin 
(mIU/L)/(glucose − 3.5)%.
All samples for hormone analysis were centrifuged 
and frozen at -20 °C. Hormone levels (insulin, C-pep-
tide, cortisol, TSH and SHBG) were determined us-
ing the radioimmunoassay method with commercially 
available kits, according to the manufacturer’s recom-
mendations (DIAsource Immuno Assays S.A., Lou-
vain-la-Neuve, Belgium).
Genomic DNA was extracted from 200 μL of pe-
ripheral whole blood with EDTA as an anticoagulant. 
Commercially available spin columns for DNA ex-
traction were used for DNA extraction, according to 
the manufacturer’s instructions (G-spin TN Genomic 
DNA Extraction Kit; Intron Biotechnology, Seoul, 
South Korea).
Genotypic analysis of the IL-10 gene polymor-
phism, -1082G/A (rs1800896), was performed using 
TaqMan® SNP Genotyping Assay (Assay ID: 
C___7514879_10) with an ABI PRISM 7000 Se-
quence Detection System (Applied Biosystems, Foster 
City, CA, USA).
Th ermocycler parameters were as follows: 95 °C for 
10 min (hold); 40 cycles at 92 °C for 15 s (denatur-
ation), 60 °C for 1 min (primer annealing and exten-
sion). Negative and positive control samples were run 
simultaneously in each real-time PCR plate analyzed. 
Th e total reaction volume per well was 25 μL with 5 
μL of DNA (1 ng/μL) used as a template.
Statistical analysis
Results were analyzed using descriptive statistical 
analysis. Continuous variables were summarized using 
sample size, mean, median, standard deviation, and 
minimum and maximum values. Signifi cance was de-
clared at a two-sided 0.05 level, unless otherwise spec-
ifi ed. Student’s t-test was used as a parameter test and 
Mann-Whitney as a non-parameter test to calculate 
distribution diff erences for continuous variables. Th e 
χ2-test and Fisher exact tests were used for variables 
measured by a nominal or ordinal scale. To detect dif-
ferences in the distributions of three or more variables, 
the ANOVA test (parameter test) and Friedman 
ANOVA test (non-parameter test) were utilized. In 
addition, factorial analysis of variables was used in 
which one variable was a specifi c group (experimental 
or control), and the other was the cytokine genotype. 
Th e Hardy-Weinberg equilibrium (deviation of ex-
pected genotype frequencies – p2 + 2 pq + q2, where pq 
represents the frequency of one of two possible alleles, 
biallelic single nucleotide polymorphism (SNP)) was 
tested with the χ2-test with one degree of freedom and 
signifi cance at p<0.05. Statistical analysis was per-
formed using Statistica 9.1 (StatSoft Inc., Tulsa, OK, 
USA, 2012).
Results
Th e baseline characteristics of the subjects are sum-
marized in Table 1. Both groups were similar in age 
and sex. Body weight (p=0.012), BMI (p=0.018), and 
waist circumference (p=0.026) were signifi cantly high-
er in the controls when compared to patients with dia-
betes. Fasting glucose and HbA1c values were higher 
(p<0.00001 and p<0.00001, respectively) in patients 
with type 2 diabetes, while insulin and C-peptide 
 values were similar in both groups. HOMA-IR was 
signifi cantly higher (p=0.000083) and HOMA-B 
(p=0.022) signifi cantly lower in diabetic group than in 
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control group. Lipid profi le analysis revealed that tri-
glyceride levels were higher (p=0.014) in diabetic 
group, while high-density lipoprotein (p=0.0045), 
low-density lipoprotein cholesterol (p<0.00001) and 
total cholesterol levels (p=0.00037) were lower in pa-
tients with diabetes than in control group, most likely 
as a consequence of treatment with statins in the for-
mer. Diabetic group had higher levels of leukocytes 
(p=0.012), fi brinogen (p=0.049) and PAI-1 (p=0.009), 
and lower levels of albumin (p=0.001) than control 
group. CRP levels were also higher in patients with 
diabetes, but the diff erence was only numerical and 
not statistically signifi cant.
Investigation of IL-10 gene polymorphisms re-
vealed that genotypes did not signifi cantly deviate 
from Hardy-Weinberg equilibrium (IL-10-1082G/A 
(rs1800896); p=0.941) indicating that in the experi-
mental population, the eff ects of selection, genetic drift, 
mutations, gene fl ow, and migration were not present. 
Th e frequency of the minor allele was 0.427 (42.7%) in 
all subjects. Th e IL-10-1082G/A genotype distribution 
in diabetic group was as follows: GG homozygous, 
29.37%; GA heterozygous, 55.94%; and AA homozy-
gous, 14.69%. Th e genotype distribution in control 
group was as follows: GG homozygous, 32.29%; GA 
heterozygous, 50.0%; and AA homozygous, 17.71%. 







Age (years) 60.1±10.3 58.8±8.4 NS
Age at diagnosis (years) 52.1±11.4 0.000001








Body weight (kg) 89.1±19.6 95.9±20.8 0.012
Body mass index (kg/m2) 32.17±5.49 34.04±6.43 0.018
Waist circumference (cm) 103.4±12.8 107.5±13.8 0.026
Systolic blood pressure (mm Hg) 135±18 140±18 0.04
Diastolic blood pressure (mm Hg) 83±11 86±9 NS
Fasting glucose (mmol/L) 10.5±4,2 5.1±0.7 <0.00001
HbA1c (%) 9.37±2.35 5.86±0.28 <0.00001
Insulin (mIU/L) 14.17 (7.17-15,2)* 12.99 (8.8-17.8)* NS
C-peptide (pmol/L) 1,106.7±559.1 1,192.8±596.8 NS
HOMA-IR 4.60 (3.35-6.3)* 3.52±2.71  0.00008
HOMA-B 30.09 (17.7-76,5)* 210.4±126.7 0.022
Cholesterol (mmol/L) 5.34±1.58 6.19±1.38 0.00037
Triglycerides (mmol/L) 2.07 (1.58-2.67)* 1.83±1.05 0.014
HDL cholesterol (mmol/L) 1.19±0.49 1.35±0.34 0.0045
LDL cholesterol (mmol/L) 3.08±1.24 4.06±1.18 <0.00001
L (×109 cells/L) 7.2±2.2 6.5±1.7 0.012
CRP (mg/L) 3.0 (1.3-5.6)* 3.1 (1.4-7.2)* NS
Fibrinogen (g/L) 3.93±1.06 3.70±0.84 0.049
PAI-1 (U/L) 4.19±1.82 3.49±1.99 0.009
Albumin (g/L) 42.60±3.43 44.13±2.70 0.001
t-test; NS = nonsignifi cant; HOMA-IR = homeostatic model assessment index of insulin resistance; HOMA-B = 
homeostatic model assessment index of beta-cell function; HDL = high-density lipoprotein; LDL = low-density lipo-
protein; L = leukocytes; CRP = C-reactive protein; PAI-1 = plasminogen activator inhibitor-1; *values represented as 
median (interquartile range)
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Th ere was no signifi cant diff erence in genotype distri-
bution between the two groups (p=0.654).
In order to evaluate the eff ect of the IL-10 geno-
type on glucose metabolism, the mean values of fasting 
glucose, HbA1c, HOMA-IR and HOMA-B were 
fi rst compared between the diabetic and control groups 
(Fig. 1). Th ese values were then compared between dif-
ferent IL-10 genotypes including all subjects (experi-
mental and control) (Fig. 2), and fi nally with the geno-
type and group affi  liation combined (Fig. 3). Th e mean 
levels of fasting glucose (p<0.000001), HbA1c 
(p<0.000001) and HOMA-IR (p=0.004312) were 
signifi cantly higher, while the mean HOMA-B 
(p=0.047508) levels were lower in patients with diabe-
tes than in controls, as expected (Fig. 1). Analysis of 
the mean fasting glucose and HbA1c levels in subjects 
with the AA genotype (‘low producers’ of IL-10) 
yielded signifi cantly higher values (p<0.000001) of 
both parameters in control and diabetic subjects. Anti-
infl ammatory eff ects were expected to be lowest in this 
group (Fig. 2). Th e interaction eff ect was not statisti-
cally signifi cant, indicating that the eff ect of a specifi c 
IL-10 genotype on the phenotype, in this case fasting 
glucose and HbA1c, was independent of the presence 
of type 2 diabetes (Fig. 3).
Th e mean HOMA-IR values were signifi cantly 
lower (p=0.003632) in subjects with the GG genotype 
(‘high producers’ of IL-10) in both groups, in which 
the expected anti-infl ammatory response was stron-
gest (Fig. 2). In contrast, the mean HOMA-B values 
Fig. 1. Mean values of fasting glucose (a), HbA1c (b), HOMA-IR (c) and HOMA-B (d) in diabetes type 2 group 
and control group.
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were lowest (p=0.000178) in subjects with the AA 
genotype (‘low producers’) with a diminished IL-10 
anti-infl ammatory response (Fig. 2). Again, the inter-
action eff ect was not statistically signifi cant; that is, the 
eff ect of a specifi c IL-10 genotype on HOMA-IR and 
HOMA-B did not depend on the presence of type 2 
diabetes (Fig. 3).
In order to investigate whether the described asso-
ciation of the IL-10 genotype and glucose meta-
bolism parameters was a consequence of other risk 
 factors (phenotype characteristics), analysis of the 
groups with diff erent genotypes encompassing all 
 subjects was performed in relation to sex, age and an-
thropometric characteristics (Table 2). Th ere was no 
statistically signifi cant diff erence between subjects 
with diff erent genotypes for the IL-10-1082G/A 
polymorphism according to age, sex, waist circumfer-
ence, or BMI.
In addition, analysis of chronic microvascular com-
plications (24-hour protein and albumin excretion, 
proliferative and non-proliferative diabetic retinopa-
thy, and diabetic polyneuropathy) in relation to a spe-
cifi c IL-10 genotype was performed (Table 3). Th ere 
was no statistical signifi cance in the development of 
microvascular complications between the groups with 
diff erent IL-10 polymorphism genotypes.
Discussion
Insulin resistance and beta cell function have a key 
role in the pathogenesis of type 2 diabetes. Results of 
the UK Prospective Diabetes Study demonstrated that 
Fig. 2. Mean values of fasting glucose (a), HbA1c (b), HOMA-IR (c) and HOMA-B (d) according to IL-10 genotype.
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impaired beta cell function was crucial for the devel-
opment and progression of type 2 diabetes21, while 
other studies implicated proinsulin secretion22, decline 
of beta cell mass23, and amyloid deposition24. In our 
study, patients with type 2 diabetes had higher 
HOMA-IR and lower HOMA-B values, clearly dem-
onstrating two key elements of the pathophysiology of 
type 2 diabetes, i.e. insulin resistance and impaired 
beta cell function. Concentrations of basal insulin and 
C-peptide were similar in both groups, probably as a 
result of compensatory insulinemia due to insulin re-
sistance in patients with diabetes.
Current research in obese individuals indicates that 
the healthy obese population has low infl ammatory 
activity as opposed to obese patients with metabolic 
syndrome25-27. Th ese fi ndings support our study where 
we found that specifi c parameters of infl ammatory ac-
tivity, such as leukocyte count, fi brinogen, serum albu-
min, and PAI-1 levels, were lower in control subjects 
than in patients with diabetes28-32. All markers of in-
fl ammation were increased in obese diabetic subjects 
except for CRP levels, where diff erence between the 
experimental and control groups was not statistically 
signifi cant. Presumably, it was due to variations in the 
Fig. 3. Mean values of fasting glucose (a), HbA1c (b), HOMA-IR (c) and HOMA-B (d) according to both 
genotype and group.
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sensitivity of CRP and circulating CRP levels between 
the groups.
Direct association of the IL-10-1082G/A poly-
morphism and type 2 diabetes remains elusive. Results 
of a meta-analysis published in 2013, which included 
10 studies, demonstrated that the IL-10-1082G/A 
polymorphism was clearly associated with type 2 dia-
betes, but only in Asian, and not in European or Afri-
can populations13. Our observation that the frequency 
of diff erent IL-10 genotypes did not vary between the 
control and diabetic groups was in agreement with this 
analysis. However, when contemplating diabetes-re-
lated traits in all subjects (control and diabetic) of a 
specifi c genotype, it is clear that the HOMA-IR val-
ues were higher and HOMA-B values lower in the 
group with the AA genotype (‘low producers’) than in 
the groups with GG or GA genotypes. Our control 
group consisted of obese subjects without diabetes but 
the criteria we applied for diabetes exclusion (fasting 
glucose <7 mmol/L, HbA1c <6.5%) resulted in the in-
clusion of so-called ‘intermediate’ patients with pre-
diabetes in our control group. Since this particular 
subset of patients has a higher risk of developing type 
2 diabetes33, we can speculate that the AA genotype of 
the IL-10 gene may occur at a higher frequency in pa-
tients with pre-diabetes than in healthy individuals. 
However, diabetes-related traits have not been fully 
established, thus infl uencing the fi nal results of this 
study. Th e infl uence of SNP polymorphism in pre-di-
abetes should be investigated in further studies with a 
larger number of subjects.
Contrary to our results, a study performed by Scar-
pelli et al. in an Italian cohort found no association 
between IL-10-1082G/A and diabetes-related traits 
(fasting glucose, HOMA-B and HOMA-IR)19. Th is 
discrepancy may be attributed to ethnic variations re-
garding the prevalence of specifi c polymorphisms in 
the IL-10 gene, as our patients were recruited solely 
from eastern Croatia. Indeed, this is the fi rst report on 
the frequency of the IL-10-1082G/A SNP in the 
Croatian population, and it is similar to previous re-
ports for the European population (42.7% and 46.9%, 
respectively)13. However, in the study by Scarpelli et 
al.19, the link between AA genotype, fasting insulin 
Table 2. Analysis of groups with diff erent genotypes according to sex, age, waist circumference 





*Age (years) 59.4±9.4 59.4±10.2 60.1± 8.0 0.92
Female: n (%) 40 (55) 82 (64) 24 (63) 0.41
Male: n (%) 33 (45) 46 (36) 14 (37)
*Waist circumference (cm) 105.6±14.4 105.5±14.4 102.8±11.1 0.54
*BMI (kg/m2) 33.2±5.9 32.8± 6.4 32.7 ± 5.9 0.86
*Data shown as mean ± SD; t-test, χ2-test





*24-h urine protein excretion (mg/L) 168.37±167.4 326.7±626.98 211.0±262.65 0.58
*24-h urine albumin excretion (mg/L) 36.68±109.14 111.2±293.4 52.20±134.67 0.69
Diabetic retinopathy Yes (%) 16 11 12
0.83
No (%) 84 89 88
Diabetic polyneuropathy Yes (%) 62 70 72
0.72
No (%) 38 30 28
*Data shown as mean ± SD; t-test, χ2-test
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and insulin resistance is reported with more prominent 
-592C/A, but not the -1082G/A, IL-10 promoter 
polymorphism. Th erefore, it is possible that in the 
Croatian population, the -1082G/A polymorphism is 
more prominent and contributes to the interindividual 
variation in BMI and insulin sensitivity.
In a study performed by Kolla et al., development 
of diabetic polyneuropathy was associated with high 
production of IL-10 (genotype -1082G/G)16, while 
Lee et al. demonstrated that high concentrations of 
IL-10 negatively correlated with diabetic retinopa-
thy18. However, we did not establish any diff erence in 
the development of microvascular complications be-
tween diff erent IL-10 polymorphism genotypes, pre-
sumably due to a small sample size.
Th e present study had several limitations. Th e pa-
tient population was relatively small and recruited ex-
clusively from eastern Croatia. Th is small patient pop-
ulation may have infl uenced study results, where IL-
10 polymorphism genotypes were associated with dia-
betes-related traits but not with diabetes or its 
microvascular complications. Furthermore, standard 
statistical analysis of the secondary phenotype data in 
case-control studies can be misleading since the asso-
ciation between a secondary phenotype and a genetic 
variant in the case and control groups can be quite dif-
ferent from their association in the general population, 
requiring a novel approach in statistical analysis34. In 
addition, since this was a cross-sectional study, disease 
outcome and prognosis in relation to a specifi c geno-
type is still unknown. Th us, a large-scale, long-term, 
prospective, population-based study with diff erent 
ethnicities is required to establish whether a relation-
ship between polymorphisms in the IL-10 gene and 
type 2 diabetes actually exists and whether it aff ects 
the prognosis of type 2 diabetes and development of 
microvascular complications.
Conclusions
In conclusion, obese patients with type 2 diabetes 
showed an increased infl ammatory activity when com-
pared to obese non-diabetic controls. We could not 
show the association between the IL-10-1082G/A 
SNP genotypes and development of type 2 diabetes and 
microvascular complications. However, we established a 
clear link between the IL-10-1082G/A polymorphism 
and diabetes-related traits, therefore specifi c genotypes 
(high producers vs. low producers) had a distinct impact 
on diabetes-related traits in all subjects.
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Sažetak
POVEZANOST POLIMORFIZMA GENA ZA INTERLEUKIN-10 (-1082G/A) 
S TIPOM 2 ŠEĆERNE BOLESTI I MIKROVASKULARNIM KOMPLIKACIJAMA 
U HRVATSKOJ POPULACIJI
S. Canecki-Varžić, I. Prpić-Križevac, S. Mihaljević, I. Bilić-Ćurčić, T. Alkhamis, J. Wagner, I. Škrlec i J. Barbić
Smanjena sekrecija protuupalnog citokina interleukina (IL)-10 opisana je u debljini, metaboličkom sindromu i tipu 2 
šećerne bolesti (T2ŠB). Međutim, nije utvrđeno može li intenzitet imunog odgovora tijekom kronične upale utjecati na 
 razvoj i/ili progresiju dijabetesa kao i razvoj mikrovaskularnih komplikacija. Cilj ove studije bio je istražiti povezanost poli-
morfi zma gena (SNP) -1082G/A za IL-10 s razvojem T2ŠB i kroničnih komplikacija. DNK za genotipizaciju se ekstrahi-
rala iz krvnih stanica 240 adipoznih ispitanika koji su podijeljeni u dvije skupine: u eksperimentalnoj skupini bilo je 144 
bolesnika s T2ŠB, a u kontrolnoj skupini 96 ispitanika usklađenih prema spolu i dobi. U skupini s T2ŠB nađene su više vri-
jednosti leukocita (p=0,012), fi brinogena (p=0,049) i inhibitora aktivacije plazminogena-1 (PAI-1) (p=0,009) te niže kon-
centracije albumina (p=0,001) nego u kontrolnoj skupini. Nije bilo statističke razlike u frekvencijama -1082G/A polimor-
fi zma gena za IL-10 (p=0,654). Kada su se gledali ishodi za specifi čni genotip u svih ispitanika, ispitanici s homozigotnim 
genotipom (AA) imali su značajno više koncentracije glukoze natašte (p<0,000001), HbA1c (p<0,000001) i HOMA-IR 
(p=0,003632) te niži indeks HOMA-B (p=0,000178) u odnosu na ispitanike s genotipovima GG i GA. Nije bilo razlike 
u genotipovima polimorfi zma IL-10 gena i razvoja nefropatije, retinopatije i polineuropatije. U zaključku, pretili bolesnici 
s T2ŠB imali su pojačanu upalnu aktivnost u usporedbi s pretilim ispitanicima bez šećerne bolesti. Nije utvrđena pove-
zanost polimorfi zma IL-10 i razvoja T2ŠB kao ni razvoja mikrovaskularnih komplikacija. Međutim, ishodi povezani s 
dijabetesom jasno su povezani s određenim genotipom IL-10.
Ključne riječi: Dijabetes tip 2; Upala; Interleukin-10; SNP-1082G/A; Mikrovaskularne komplikacije
